Relief Therapeutics Holding SA (SWX: RLF)
Switzerland
· Delayed Price · Currency is CHF 3.890
-0.470 (-10.78%)
Dec 3, 2024, 12:23 PM CET
RLF Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Operating Revenue | 8.59 | 6.03 | 6.08 | 3.32 | - | - | Upgrade
|
| Other Revenue | 0.01 | - | - | - | - | - | Upgrade
|
| Revenue | 8.6 | 6.03 | 6.08 | 3.32 | - | - | Upgrade
|
| Revenue Growth (YoY) | 45.04% | -0.79% | 83.11% | - | - | - | Upgrade
|
| Cost of Revenue | 2.7 | 1.92 | 1.25 | 0.75 | - | - | Upgrade
|
| Gross Profit | 5.9 | 4.11 | 4.83 | 2.57 | - | - | Upgrade
|
| Selling, General & Admin | 14.17 | 19.43 | 24.05 | 15.14 | 5.47 | 0.92 | Upgrade
|
| Research & Development | 1.13 | 1.33 | 12.39 | 19.02 | 13.67 | - | Upgrade
|
| Other Operating Expenses | -0.12 | -0.12 | -0.51 | 0.61 | 0.23 | 0.03 | Upgrade
|
| Operating Expenses | 18.22 | 23.95 | 39.79 | 36.81 | 19.36 | 0.95 | Upgrade
|
| Operating Income | -12.33 | -19.84 | -34.96 | -34.24 | -19.36 | -0.95 | Upgrade
|
| Interest Expense | - | -0.03 | -0.13 | -0.19 | -0.1 | -0.13 | Upgrade
|
| Interest & Investment Income | 0.64 | 0.09 | 0.02 | 0.04 | 0.01 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.07 | -0.07 | -0.37 | 0.06 | -0.4 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.62 | -0.86 | -1.79 | -1.1 | -0.05 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -16.38 | -20.7 | -37.24 | -35.43 | -19.9 | -1.05 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -1.1 | - | - | Upgrade
|
| Impairment of Goodwill | -6.02 | -6.02 | -1.64 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.45 | -0.05 | -1.2 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.13 | 0.13 | - | - | 3.38 | - | Upgrade
|
| Asset Writedown | -34.05 | -89.88 | -24.78 | - | 11.2 | -11.2 | Upgrade
|
| Legal Settlements | - | - | - | - | - | 0.16 | Upgrade
|
| Other Unusual Items | 4.78 | 4.78 | 8.89 | 1.06 | 0.25 | -0.07 | Upgrade
|
| Pretax Income | -51.54 | -111.68 | -54.32 | -35.53 | -6.26 | -12.16 | Upgrade
|
| Income Tax Expense | -5.3 | -13.5 | -3.53 | -0.82 | 1.57 | -4.7 | Upgrade
|
| Net Income | -46.24 | -98.18 | -50.79 | -34.71 | -7.83 | -7.46 | Upgrade
|
| Net Income to Common | -46.24 | -98.18 | -50.79 | -34.71 | -7.83 | -7.46 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 11 | 9 | 6 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 11 | 9 | 6 | 5 | Upgrade
|
| Shares Change (YoY) | 14.39% | 11.18% | 17.67% | 48.89% | 14.71% | 2.62% | Upgrade
|
| EPS (Basic) | -3.70 | -8.35 | -4.80 | -3.86 | -1.30 | -1.42 | Upgrade
|
| EPS (Diluted) | -3.70 | -8.35 | -4.80 | -3.86 | -1.30 | -1.42 | Upgrade
|
| Free Cash Flow | -10.39 | -18.06 | -24.16 | -35.72 | -18.25 | -0.73 | Upgrade
|
| Free Cash Flow Per Share | -0.83 | -1.54 | -2.29 | -3.98 | -3.03 | -0.14 | Upgrade
|
| Gross Margin | 68.56% | 68.17% | 79.44% | 77.42% | - | - | Upgrade
|
| Operating Margin | -143.38% | -328.86% | -574.92% | -1030.89% | - | - | Upgrade
|
| Profit Margin | -537.79% | -1627.40% | -835.22% | -1045.02% | - | - | Upgrade
|
| Free Cash Flow Margin | -120.83% | -299.32% | -397.29% | -1075.52% | - | - | Upgrade
|
| EBITDA | -9.81 | -17.06 | -31.49 | -32.38 | -19.36 | -0.95 | Upgrade
|
| EBITDA Margin | -114.13% | -282.76% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2.52 | 2.78 | 3.47 | 1.86 | 0 | 0 | Upgrade
|
| EBIT | -12.33 | -19.84 | -34.96 | -34.24 | -19.36 | -0.95 | Upgrade
|
| EBIT Margin | -143.38% | - | - | - | - | - | Upgrade
|
| Revenue as Reported | 8.89 | 6.33 | 7.11 | 4.49 | 0.27 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.